<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02580149</url>
  </required_header>
  <id_info>
    <org_study_id>FBF-Tica-Clopi</org_study_id>
    <nct_id>NCT02580149</nct_id>
  </id_info>
  <brief_title>The Effect of Ticagrelor or Clopidogrel on Endothelial Function During Acute and Chronic Treatment</brief_title>
  <official_title>The Effect of an Acute Dose of Ticagrelor or Clopidogrel and of Treatment for 14 Days on Ischemia-reperfusion Induced Endothelial Dysfunction of the Forearm Vasculature in Healthy Male Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael Wolzt, Prof. MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate if treatment with ticagrelor can mitigate the transient loss of&#xD;
      endothelium-dependent vasodilatation of the resistance vasculature following a short period&#xD;
      of ischemia, compared with clopidogrel at standard clinical doses. The effect of ticagrelor&#xD;
      or clopidogrel will be studied after a loading dose and after a two weeks period of regular&#xD;
      intake on FBF in response to the vasodilators acetylcholine or nitroglycerin before and 10&#xD;
      min after a 20 min forearm ischemia, respectively.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ischemia-reperfusion (IR) causes tissue injury. Preclinical animal data suggest that&#xD;
      ticagrelor but not clopidogrel protects against IR injury due to inhibition of cellular&#xD;
      adenosine uptake and NO-synthase stimulation. It is unclear if this action is part of the&#xD;
      beneficial clinical effect of ticagrelor in patients with a history of acute coronary&#xD;
      syndrome. The preventive action of ticagrelor on IR injury may also be of interest for the&#xD;
      peripheral vasculature, where IR injury is known to result in endothelial dysfunction. This&#xD;
      study aims to investigate if treatment with ticagrelor can mitigate the transient loss of&#xD;
      endothelium-dependent vasodilatation of the resistance vasculature following a short period&#xD;
      of ischemia, compared with clopidogrel at standard clinical doses. We will study the effect&#xD;
      of ticagrelor or clopidogrel after a loading dose and after a two weeks period of regular&#xD;
      intake on forearm blood flow (FBF) reactivity in response to the vasodilators acetylcholine&#xD;
      (ACh; endothelium-dependent agonist) or nitroglycerin (GTN; endothelium-independent&#xD;
      vasodilator) before and 10 min after a 20 min forearm ischemia, respectively&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve (AUC) of Forearm blood flow (FBF) measurements of Acetylcholin (ACh) induced vasodilatation</measure>
    <time_frame>Change of the AUC before and 10 min after forearm ischemia</time_frame>
    <description>To test the effect of ticagrelor or clopidogrel on ACh-induced vasodilatation of the forearm resistance vasculature as assessed by FBF measurement before and 10 min after a 20 min forearm ischemia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) of Forearm blood flow (FBF) measurements of Glyceroltrinitrate (GTN) induced vasodilatation</measure>
    <time_frame>Change of AUC before and 10 min after forearm ischemia</time_frame>
    <description>To test the effect of ticagrelor or clopidogrel on GTN-induced vasodilatation of the forearm resistance vasculature as assessed by FBF measurement before and 10 min after a 20 min forearm ischemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Expected) Peak plasma concentration of ticagrelor or clopidogrel</measure>
    <time_frame>2.5 h after IMP intake</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Ischemia</condition>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Loading dose of 180 mg on day one, followed by a regular intake (90 mg twice daily) for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Loading dose of 600 mg on day one, followed by a regular intake (75 mg once daily) for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Subjects will receive an oral loading dose of 180 mg ticagrelor on study day&#xD;
1 followed by a maintenance dose of 90 mg twice daily for 14 days (until study day 15).</description>
    <arm_group_label>Ticagrelor</arm_group_label>
    <other_name>Brilique</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Subjects will receive a loading dose of 600 mg clopidogrel on the first study day followed by a maintenance dose of 75 mg once daily for 14 days</description>
    <arm_group_label>Clopidogrel</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male subjects; 18 - 40 years of age&#xD;
&#xD;
          -  Body mass index between 18 and 27 kg/m2&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Normal findings in medical &amp; bleeding history&#xD;
&#xD;
          -  Non-smoking&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Regular intake of any medication including OTC drugs and herbals within 2 weeks before&#xD;
             IMP administration&#xD;
&#xD;
          -  Known coagulation disorders (e.g. haemophilia, von WillebrandÂ´s disease)&#xD;
&#xD;
          -  Known disorders with increased bleeding risk (e.g. peridontosis, haemorrhoids, acute&#xD;
             gastritis, peptic ulcer, intestinal ulcer)&#xD;
&#xD;
          -  Known sensitivity to common causes of bleeding (e.g. nasal)&#xD;
&#xD;
          -  History of thromboembolism&#xD;
&#xD;
          -  History of occlusive vascular diseases&#xD;
&#xD;
          -  History of vascular anomalies&#xD;
&#xD;
          -  Impaired liver function (AST, ALT, gGT, bilirubin &gt;2 x ULN)&#xD;
&#xD;
          -  Impaired renal function (serum creatinine &gt; 1.3 mg/dl)&#xD;
&#xD;
          -  Any other relevant deviation from the normal range in clinical chemistry, haematology&#xD;
             or urine analysis&#xD;
&#xD;
          -  HIV-1/2-Ab, HbsAg or HCV-Ab positive serology&#xD;
&#xD;
          -  Systolic blood pressure above 145 mmHg, diastolic blood pressure above 95 mmHg&#xD;
&#xD;
          -  Known allergy against any test agent under study&#xD;
&#xD;
          -  Regular daily consumption of more than on litre of xanthine-containing beverages or&#xD;
             more than 40g alcohol&#xD;
&#xD;
          -  Participation in another clinical trial during the preceding 3 weeks&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Wolzt, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Pharmacology, Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Vienna, Department of Clinical Pharmacology</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>October 15, 2015</study_first_submitted>
  <study_first_submitted_qc>October 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2015</study_first_posted>
  <last_update_submitted>September 19, 2016</last_update_submitted>
  <last_update_submitted_qc>September 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Michael Wolzt, Prof. MD</investigator_full_name>
    <investigator_title>Prof. MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

